In his role at Flagship Pioneering, Paul works with Flagship growth company CEOs and their teams to achieve the best attainable value for each company. He also serves on the boards of selected Flagship companies. As a member of Flagship’s senior leadership, Paul is involved in strategic and operational aspects of Flagship, including leading Pioneering Medicines.
Pioneering Medicines is a newly formed initiative dedicated to conceiving and developing an innovative pipeline of first-in-category therapeutic products that leverage Flagship’s platform companies and extend beyond the programs its companies develop on their own. Pioneering Medicines plans to forge one or more strategic partnerships with biopharmaceutical companies with the aim of extending the partners’ access to multiple novel scientific platforms unique to the Flagship ecosystem of companies. Paul also serves on the board of directors at Seres Therapeutics (NASDAQ: MCRB) and Integral Health.
Paul joins Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb. Since 2015, Paul was the Senior Vice President of Strategy and Business Development where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy, and for pursuing strategic transactions to access external innovation, enhance BMS’s capabilities and strengthen the company’s portfolio. From 2002 to 2015, Paul held a series of leadership roles within BMS’ R&D organization overseeing strategy, portfolio and project management, and clinical and business operations.
Prior to his time at BMS, Paul spent nine years at Mercer Management Consulting. He holds a bachelor’s degree from Dartmouth College and an M.B.A. from the J.L. Kellogg School of Management at Northwestern University.